Zheng Hua, Zeltsman Masha, Zauderer Marjorie G, Eguchi Takashi, Vaghjiani Raj G, Adusumilli Prasad S
Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, NY, USA.
Department of Oncology, Beijing Chest Hospital, Capital Medical University, 97 Machang, Tongzhou District, Beijing, China.
Immunotherapy. 2017 Sep;9(11):913-927. doi: 10.2217/imt-2017-0052.
Spurred by the survival benefits seen with the use of checkpoint blockade in non-small-cell lung cancer (NSCLC), there has been a growing interest in the potential applications of immunotherapy. Despite this, the objective response rate for single-agent immunotherapy remains ≤20% in patients with advanced NSCLC. A combinatorial approach that utilizes both chemotherapy and immunotherapy is a potential strategy to increase antitumor efficacy. Accumulating evidence has shown that the immunomodulatory effects of chemotherapeutic agents can be exploited in a combinational approach. Herein, we review the influence of specific chemotherapeutic agents on the tumor immune microenvironment in preclinical and clinical studies, and establish the rationale for combination chemoimmunotherapy for the treatment of NSCLC.
受非小细胞肺癌（NSCLC）中使用检查点阻断所带来的生存益处的推动，人们对免疫疗法的潜在应用越来越感兴趣。尽管如此，晚期NSCLC患者中单一药物免疫疗法的客观缓解率仍≤20%。将化疗和免疫疗法结合使用的联合方法是提高抗肿瘤疗效的潜在策略。越来越多的证据表明，化疗药物的免疫调节作用可用于联合治疗方法。在此，我们回顾了临床前和临床研究中特定化疗药物对肿瘤免疫微环境的影响，并确立了联合化疗免疫疗法治疗NSCLC的理论依据。
